Vaccination of Risk Groups in England Using the 13 Valent Pneumococcal Conjugate Vaccine: Economic Analysis

Overview

Journal BMJ

Specialty General Medicine

Date 2012 Oct 30

PMID 23103369

Citations 31

Authors

Mark H Rozenbaum

Albert Jan van Hoek

Douglas Fleming

Caroline L Trotter

Elizabeth Miller

W John Edmunds

Affiliations

Soon will be listed here.

Abstract

Objective: To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.

Design: Economic evaluation using a cohort model from the perspective of healthcare providers.

Setting: England.

Participants: People aged 2 years and older at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised immune system; chronic heart, liver, or respiratory disease; or diabetes.

Main Outcome Measures: Costs, gains in life years and quality adjusted life years (QALYs), and incremental cost effectiveness ratios.

Results: Increasing indirect protection resulting from the vaccination programme of infants using the 13 valent pneumococcal conjugate vaccine means that the burden of disease preventable by targeting high risk groups will diminish in time. Under base case assumptions--that is, no overall impact on non bacteraemic pneumonia in high risk groups and assuming the high risk vaccination programme would be launched two to three years after the infant programme--the incremental cost effectiveness ratio was estimated to be more than £30,000 (€37,216; $48,210) per QALY gained for most risk groups. If, however, the vaccine does not offer protection against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced concomitantly with the infant 13 valent pneumococcal conjugate vaccination programme then vaccinating high risk people would (more) likely be cost effective. Sensitivity analyses showed that the cost effectiveness was particularly sensitive to assumed herd benefits and vaccine efficacy estimates.

Conclusion: Under base case assumptions it is unlikely that a pneumococcal vaccination programme aimed at risk groups could be considered cost effective. Uncertainty could be substantially reduced by establishing the effectiveness of the 13 valent pneumococcal conjugate vaccine against non-bacteraemic pneumococcal pneumonia, particularly in at risk groups.

Citing Articles

Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.

Ta A, Kuhne F, Laurenz M, von Eiff C, Warren S, Perdrizet J Infect Dis Ther. 2024; 13(6):1333-1358.

PMID: 38733494 PMC: 11128430. DOI: 10.1007/s40121-024-00977-4.

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions.

Rozenbaum M, Chilson E, Farkouh R, Huang L, Cane A, Arguedas A Infect Dis Ther. 2024; 13(4):745-760.

PMID: 38491269 PMC: 11058137. DOI: 10.1007/s40121-024-00944-z.

Pneumococcal serotypes and risk factors in adult community-acquired pneumonia 2018-20; a multicentre UK cohort study.

Lansbury L, Lawrence H, McKeever T, French N, Aston S, Hill A Lancet Reg Health Eur. 2024; 37:100812.

PMID: 38170136 PMC: 10758948. DOI: 10.1016/j.lanepe.2023.100812.

Herd immunity in older adults from a middle-income country: A time-series trend analysis of community-acquired pneumonia mortality 2003-2017.

Sanchez C, Rivera-Lozada O, Lozada-Urbano M, Best-Bandenay P Health Sci Rep. 2023; 6(5):e1224.

PMID: 37152218 PMC: 10155615. DOI: 10.1002/hsr2.1224.

The effect of influenza and pneumococcal vaccination in the elderly on health service utilisation and costs: a claims data-based cohort study.

Storch J, Fleischmann-Struzek C, Rose N, Lehmann T, Mikolajetz A, Maddela S Eur J Health Econ. 2021; 23(1):67-80.

PMID: 34283323 PMC: 8882088. DOI: 10.1007/s10198-021-01343-8.

References

French N, Gordon S, Mwalukomo T, White S, Mwafulirwa G, Longwe H . A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010; 362(9):812-22. PMC: 2873559. DOI: 10.1056/NEJMoa0903029. View

Drummond M, Jefferson T . Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996; 313(7052):275-83. PMC: 2351717. DOI: 10.1136/bmj.313.7052.275. View

Jit M . The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect. 2010; 61(2):114-24. DOI: 10.1016/j.jinf.2010.04.008. View

Smith K, Wateska A, Nowalk M, Raymund M, Nuorti J, Zimmerman R . Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 2012; 307(8):804-12. PMC: 3924773. DOI: 10.1001/jama.2012.169. View

Choi Y, Jit M, Gay N, Andrews N, Waight P, Melegaro A . 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?. PLoS One. 2011; 6(10):e26190. PMC: 3193519. DOI: 10.1371/journal.pone.0026190. View

Oostenbrink R, A Moll H, Essink-Bot M . The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol. 2002; 55(8):791-9. DOI: 10.1016/s0895-4356(02)00448-1. View

McDavid Harrison K, Song R, Zhang X . Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr. 2009; 53(1):124-30. DOI: 10.1097/QAI.0b013e3181b563e7. View

Musher D, Sampath R, Rodriguez-Barradas M . The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence?. Clin Infect Dis. 2011; 52(5):633-40. DOI: 10.1093/cid/ciq207. View

Miller E, Andrews N, Waight P, Slack M, George R . Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011; 29(49):9127-31. DOI: 10.1016/j.vaccine.2011.09.112. View

10.

Klugman K, Madhi S, Huebner R, Kohberger R, Mbelle N, Pierce N . A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003; 349(14):1341-8. DOI: 10.1056/NEJMoa035060. View

11.

Melegaro A, Edmunds W . Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004; 22(31-32):4203-14. DOI: 10.1016/j.vaccine.2004.05.003. View

12.

Bennett J, Sumner 2nd W, Downs S, Jaffe D . Parents' utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000; 154(1):43-8. View

13.

Huss A, Scott P, Stuck A, Trotter C, Egger M . Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009; 180(1):48-58. PMC: 2612051. DOI: 10.1503/cmaj.080734. View

14.

Trotter C, Waight P, Andrews N, Slack M, Efstratiou A, George R . Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996-2006. J Infect. 2009; 60(3):200-8. DOI: 10.1016/j.jinf.2009.12.008. View

15.

Melegaro A, Choi Y, George R, Edmunds W, Miller E, Gay N . Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect Dis. 2010; 10:90. PMC: 2867993. DOI: 10.1186/1471-2334-10-90. View

16.

Rozenbaum M, Sanders E, van Hoek A, Jansen A, van der Ende A, Dobbelsteen G . Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010; 340:c2509. DOI: 10.1136/bmj.c2509. View

17.

van Hoek A, Andrews N, Waight P, Stowe J, Gates P, George R . The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012; 65(1):17-24. DOI: 10.1016/j.jinf.2012.02.017. View

18.

Hak E, Grobbee D, Sanders E, Verheij T, Bolkenbaas M, Huijts S . Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008; 66(9):378-83. View

19.

Rozenbaum M, Hak E, van der Werf T, Postma M . Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther. 2010; 32(8):1517-32. DOI: 10.1016/j.clinthera.2010.06.016. View

20.

Zakikhany K, Degail M, Lamagni T, Waight P, Guy R, Zhao H . Increase in invasive Streptococcus pyogenes and Streptococcus pneumoniae infections in England, December 2010 to January 2011. Euro Surveill. 2011; 16(5). View